← Back to Search

Other

BMX-010 for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by BioMimetix JV, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, at least 18 years of age at the time of consent;
Diagnosis of AD, as defined by the criteria of Hanifin and Rajka, stable in the last 4 weeks, with onset at least 6 months prior to screening (information obtained from medical chart or subject's physician, or directly from the subject).
Timeline
Screening 31 days
Treatment Varies
Follow Up 15 days

Summary

This trial tests a product for AD: Subjects get 2 doses/day for 28 days, weekly visits to check progress, followed by a final visit 2 weeks later. Clinical assessors will be blind.

Who is the study for?
Adults at least 18 years old with stable Atopic Dermatitis (AD) covering 2-25% of their body, excluding certain areas. They must have an EASI score of ≥5 and a vIGA-AD score of ≥2. Women must use two contraception methods during the trial and one month after. Participants cannot have AD only on hands/feet, used certain treatments recently, or be pregnant.
What is being tested?
The trial is testing BMX-010 applied twice daily for 28 days against a placebo in adults with Atopic Dermatitis. It's blinded so neither participants nor assessors know who gets the real treatment. The study checks how the drug moves in the body and its effectiveness.
What are the potential side effects?
Potential side effects are not specified here but generally could include skin irritation, redness, itching or worsening of dermatitis symptoms due to either BMX-010 or placebo application.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with atopic dermatitis for at least 6 months and it has been stable for the last 4 weeks.
Select...
I have eczema affecting 2-5% of my body, not including sensitive areas.
Select...
I am a candidate for cream or ointment treatment for my skin condition.
Select...
I am willing to use a moisturizer of my choice during the study.

Timeline

Screening ~ 31 days
Treatment ~ Varies
Follow Up ~15 days
This trial's timeline: 31 days for screening, Varies for treatment, and 15 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Eczema Area and Severity Index at Week 4
Incidence of treatment emergent adverse events and changes from baseline in vital signs and clinical laboratory parameters
Secondary study objectives
Change from baseline in Body Surface Area x validated Investigator Global Assessment of Atopic Dermatitis scoreat Weeks 1, 2, 3, and 4
Change from baseline in Eczema Area and Severity Index at weeks 1, 2, and 3.
Change from baseline in Modified Pruritus Numerical Rating Scale (Current Itch Intensity; 30 minutes and 4 hours post-dose) on Day 1.
+6 more
Other study objectives
Change and percent change from baseline of subject-reported Patient-Oriented Eczema Measure (POEM) scores to Week 4.
Change from baseline in answers on the subject reported PRO questions regarding itching at Weeks 1, 2, 3 and 4

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Study Drug Treated, BMX-010 0.5%Active Control1 Intervention
n=72
Group II: Study Drug Treated, BMX-010 0.1%Active Control1 Intervention
n=72
Group III: Placebo TreatedPlacebo Group1 Intervention
n=72

Find a Location

Who is running the clinical trial?

Innovaderm Research Inc.OTHER
48 Previous Clinical Trials
3,117 Total Patients Enrolled
BioMimetix JV, LLCLead Sponsor
10 Previous Clinical Trials
594 Total Patients Enrolled

Media Library

BMX-010 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05491447 — Phase 2
Atopic Dermatitis Research Study Groups: Study Drug Treated, BMX-010 0.5%, Study Drug Treated, BMX-010 0.1%, Placebo Treated
Atopic Dermatitis Clinical Trial 2023: BMX-010 Highlights & Side Effects. Trial Name: NCT05491447 — Phase 2
BMX-010 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05491447 — Phase 2
~0 spots leftby Nov 2024